Pertussis vaccines vary in quality, safety, and efficacy according to the production strains of Bordetella pertussis, the method of manufacture, and quality control procedures. It is therefore not justifiable to combine information on the incidence, nature, and severity of reactions after all manufacturers' pertussis vaccines as if they were a single product. Attempts were made to collect information on all suspected cases of severe reactions that occurred after administration of about 15 million doses of Wellcome pertussis vaccines in the United Kingdom and Northern Ireland from 1964 to mid-1977. Altogether six deaths, six neurological reactions with sequelae, and 17 convulsions without sequelae were reported, but some were clearly not attributable to the vaccine, while, in other cases, the available information was inadequate for assessing the role of vaccination. Neurological disorders, similar to those reported in a few children after pertussis vaccination, occur unexpectedly in apparently healthy infants at the recommended age for immunisation, so chance association between vaccination and these events can be expected in some children. The Joint Committee on Vaccination and Immunisation has made several recommendations aimed at reducing severe reactions after pertussis vaccination. These include replacing plain vaccine with aluminium-adsorbed vaccine, but there is no clear evidence that the aluminium-adsorbed vaccine produces fewer reactions than the plain.
Introduction
Vaccine manufacturers have an obligation to collect and consider information on reactions after administration of their products. To meet this obligation they rely on doctors to provide full case reports on adverse clinical events after vaccination. With pertussis vaccines there is a prevailing assumption that all manufacturers' preparations are so similar in quality, safety, and efficacy that there is no need to distinguish between them or acknowledge the possibility of differences in their effects on children. Consequently, public discussions of reactions pay little or no regard to individual manufacturer's products, whereas there may be substantial differences between them. Further difficulties arise from the fact that pertussis vaccines are routinely administered to infants at an age when serious clinical disorders of unknown cause are particularly likely to occur or become evident.
Allegations that pertussis vaccine might be causing permanent brain damage to 60 to 80 children a year, or 1 or 2 per 100 000 children, in the United Kingdom'-6 stimulated investigation into the incidence of brain damage and other adverse reactions after Wellcome pertussis-containing vaccines. The incidence of these reactions was considered against the background of serious clinical conditions of unknown cause that occur in infants of vaccination age. Information was sought from publications, hospital discharge records, and the Committee on Safety of Medicines.
Case tracing through publications Dick 9 Dick later referred to two patients he had personally seen in Northern Ireland, but it was suggested9 that these had been described in previous publications1 "0 as having transient neurological complications after an early batch of diphtheria, tetanus, pertussis, and poliomyelitis vaccine. That vaccine had not been prepared by Wellcome, but no information was available on the source of the vaccines given to other children.
Kulenkampffet al reported in 1974"1 that about 50 children had been seen at the Hospital for Sick Children, London, from January 1961 to December 1972 because of neurological illness thought to be due to diphtheria, tetanus, and pertussis (DTP) vaccine. Although these children were seen months or years after the event, the authors claimed that they had adequate data on the time between vaccination and onset of symptoms in 36 cases. There was no indication whether Wellcome vaccines were implicated in any of the cases; none had been reported to the manufacturer and the authors did not supply information on request on the manufacturers of the vaccines, normally recorded on children's immunisation cards.
In 1977 Stewart"2 asserted that a strong relationship existed between pertussis vaccination and neurological reactions in 79 of the 160 cases he had investigated. He was able to identify Wellcome vaccine in three patients: one had had a convulsion three hours after vaccination, one had an encephalopathy already known to the manufacturer and included in '6 Wellcome pertussis vaccine has consistently been shown to contain agglutinogen 317-20; it has met the World Health Organisation's potency requirements, even when they were higher than British requirements2"-23; and it has been found to be more protective than another manufacturer's vaccine. 24 There are sound reasons why differences between various manufacturers' vaccines could be expected. Production strains of Bordetella pertussis are selected by each manufacturer according to representation of major serotypes, growth characteristics in the culture medium of choice, toxigenicity and ease or speed of detoxification, and potential protective qualities as assessed by the mouse potency test. There is strain variation in agglutinability, growth requirements, haemagglutination, mouse toxicity, alum precipitability, and protective properties, and these characteristics are readily lost, independently of each other, on subculture.25 The mouse pathogenicity of a strain seems to be Neurological disorders reported after pertussis vaccination do not conform with any consistent pattern but tend to represent the spectrum of neurological conditions that develop spontaneously among unvaccinated infants. Immunisation schedules require at least three doses of pertussis vaccine to be given to infants when they are between 3 and 18 months of age-a period when first convulsions are not uncommon in the previously healthy. Some 51)0 of children have a convulsion by the age of 5 years8' 82: 2 to 40o have a febrile convulsion82-85 more commonly between the ages of 6 and 24 months8' and most prolonged between 9 and 15 months. Griffith8 estimated that the incidence of first convulsions in children aged 6 to 18 months was between 1 and 3 per 100 000 children per day, basing his estimate on the results of a survey by general practitioners 86 and from surveillance of unvaccinated controls in the pertussis vaccine trials of the 1950s44 and in the measles vaccines trials of the 1960s.8 Epilepsy follows a febrile convulsion in about 20, of the children,83 the risk of sequelae depending on the duration of the fit. 81 After administration of some 15 million doses of Wellcome vaccine, the expected number of first convulsions occurring by chance within 24 hours of any of the three injections was about 250, with 5 to 10 cases of permanent brain damage. The fact that only 25 cases of neurological reactions, with or without sequelae, were reported may have been due partly to administration of some doses of vaccine to children under 6 months of age, who have a lower background incidence of first convulsions; partly to precautions taken not to vaccinate children not in good health; and partly to some degree of under-reporting. The results of a recent epidemiological survey in the Oxford area confirmed the view that febrile convulsions are uncommon after pertussis vaccination.85
In the Medical Research Council's whooping cough vaccines trials 56 000 doses were administered and 15 children were reported to have had convulsions during the ensuing 28 days, six during the first 72 hours. The incidence of convulsions during the first three days was therefore about 4 per 100 000 children per day, somewhat higher than the background incidence. Fever commonly occurs during the first 12 hours after vaccination, and although it may not exceed that recorded after smallpox vaccination,"8 it might be sufficient to affect infants with a particularly low threshold for febrile convulsions, irrespective of the cause of the fever. Pollock was recently reported to have encountered six cases of convulsions, five during the first 24 hours, after administration of 80 000 doses of an undisclosed DTP preparation, whereas no convulsions occurred after 73 000 doses of a diphtheria-tetanus vaccine. 89 Brody and Sorley"0 described a child who was vaccinated, possibly during an attack of whooping cough, and had a mild encephalitis a fortnight later. Three further doses of pertussis vaccine were given, each followed by progressively more severe exacerbations of the encephalitis, but an encephalitic episode also occurred unrelated to vaccination. It is also noteworthy that twins feature in several reports of neurological reactions after pertussis vaccination.10 11 [91] [92] [93] [94] No significant progress seems to have been made in unravelling the problem since an annotation on encephalopathy and pertussis vaccination was published in1950. 95 clinical events in recently vaccinated infants should be reported without delay to the Committee on Safety of Medicines and, whenever possible, to the manufacturers so that they can participate early in discussions and investigations; otherwise they may be left to learn of the event only through a summary statement months or years later.
The various expert committees appointed to investigate or advise on the use of pertussis vaccines rarely communicate or consult with manufacturers, possibly because they believe that the manufacturers do not have unique knowledge, experience, or investigative capacity relevant to the committees' activities. In few other fields of high technology production is advice issued to all potential users of a product without prior consultation with the manufacturers.
Perhaps the greatest difficulty encountered by manufacturers of pertussis vaccine results from the administration of their products on three separate occasions to 70 or 800°of all apparently healthy infants, a significant proportion of whom are likely at that age to have a sudden, unexpected, and serious disorder of unknown cause. Should that tragedy occur within a short period of vaccination, how is it to be decided whether it was chance or a vaccine-provoked phenomenon? The severity of intoxication from lithium treatment has been thought to vary with the serum concentrations. Thus anorexia, diarrhoea, vomiting, loss of weight, and tremor are common findings when concentrations exceed 1 5 mmol(mEq)/l; and generalised coarse tremor, hypertonia, and hyperactive reflexes, epileptiform seizures, and coma have been described in patients with concentrations exceeding 4 mmol/l.' We, however, report a case of severe central nervous system (CNS) toxicity that went unrecognised for many weeks because the serum concentrations of lithium were in the normal therapeutic range.
Case report
A 26-year-old gardener had a 10-year history of admissions for manic depressive psychosis. He required considerable supervision in his work and was a shy, dependent, immature man with difficulties in social skills. For four years he had been taking 100 mg phenytoin sodium and 30 mg phenobarbitone three times a day after several episodes of loss of consciousness. He continued with this treatment throughout. Electroencephalography (EEG) showed 4-6 cps theta rhythm with occasional left-sided emphasis, especially in the frontal area.
In September 1973 he was admitted to hospital with hypomania and stabilised with lithium carbonate (Priadel) 1200 mg by mouth daily. Morning serum concentrations were initially in the therapeutic range but then began to fall, though the dosage remained constant (table). Over the next few months stepped increases in dosage to 2400 mg daily produced only a moderate response in serum concentrations.
He was readmitted on 19 June 1974 with a further hypomanic episode. During the previous two months he had developed a coarse regular tremor, mainly in the legs. He looked generally unwell and had been losing weight. His appetite was poor but he did not have diarrhoea, abdominal pain, nausea, or polyuria. On During the coma he was given only intravenous fluids. Results of investigations were: plasma sodium 139 mmol(mEq)/l, potassium 3-8 mmol/l, bicarbonate 30 mmol/l, urea 4 6 mmol/l (28 mg/100 ml), and protein 66 g/l; packed cell volume 0 41 (41 %); white cell count 9 x 109/l (9000/mm3), normal differential; erythrocyte sedimentation rate 1 mm in first hour; midstream specimen of urine, no pathogens; EEG, 4-6 cps theta activity with proximal bursts of 1-2 cps throughout and no focal features; chest radiograph normal.
Two days later he was up and about. Tremor was still pronounced, however, though less coarse. He made steady progress and was followed up regularly as an outpatient. Phenytoin sodium 100 mg and phenobarbitone 30 mg three times daily were continued but he was not given lithium. The fine tremor took about six months to disappear, and two years after the episode he was well and had needed no further admissions.
Discussion
This patient had a history suggestive of chronic brain damage or epilepsy or both and was taking phenytoin sodium. The case raises several questions.
(1) Why was there a gradual fall in the serum lithium concentrations despite steady dosage after treatment was first begun ? Eventually the patient's requirements for lithium doubled, though his serum concentration remained in the therapeutic range (see table) .
(2) Why did his serum lithium concentration not correlate with the degree of clinical toxicity ? (3) Is there any interaction between lithium carbonate and phenytoin sodium that could account for the severe CNS toxic reaction despite a normal blood concentration ?
The patient's parents were confident that he had been taking the lithium tablets while being treated as an outpatient; during the last month, when he was an inpatient, this was supervised. Lithium was estimated with a standard flame photometer to within 01 mmol/l. There is no reason to believe that this was inaccurate.
Lithium is usually measured in serum with the assumption that dynamic equilibrium is established between tissues and blood stream. Red blood cells (RBC), however, concentrate lithium and there may be important interindividual differences in RBC :plasma ratios. These differences are partly genetic2 but may be related to depression3 and manic depressive psychosis.4 The RBC plasma ratio in any one individual appears to be stable over time.5 An important factor in lithium toxicity in some patients may be the RBC lithium concentration or the ratio of this to the plasma lithium concentration. It would be well if these determinations could be made in patients with toxic symptoms in the absence of high serum lithium concentrations.
Another explanation is suggested by the work of Graham-Smith and Green,6 7 who investigated CNS hydroxytryptamine function in rats. They found that lithium and phenytoin sodium have several similar pharmacological properties. In a series of controlled investigations they observed that hyperactivity was significantly enhanced when a
